At GPI, working daily with price and reimbursement data, we have seen a range of PMA trends across high unmet need areas such as orphan/rare diseases. Increasing pharma focus on rare diseases resulted in payers having to adapt their strategies of recent, often…
By Musa Kureshy, Business Development Manager & Tom Brockbank, Senior Consultant On Tuesday 16th of June, new research was published by scientists from Oxford University which showed that the use of Dexamethasone, a low-dose steroid treatment, on patients suffering from COVID-19 reduced deaths…
By Ines Dieringer, Associate Consultant at Global Pricing Innovations Belgium, the Netherlands, and Ireland are aiming to undertake a joint Health Technology Assessment (HTA) through the Beneluxa agreement of Zolgensma, Novartis’ gene therapy medication to treat spinal muscular atrophy (SMA)1. Zolgensma is a…
